Promising combo therapy for recurrent head and neck cancer enters human trials
NCT ID NCT07213934
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study tests whether combining radiation therapy (either standard X-ray or proton beam) with an immunotherapy drug (pembrolizumab) before surgery is safe and effective for people with recurrent head and neck cancer. About 40 participants will receive the combination treatment, then undergo surgery to remove their tumor. The goal is to see if this approach can shrink tumors more than current treatments and improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Cincinnati Medical Center
RECRUITINGCincinnati, Ohio, 45219, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.